Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
5.50
-0.36 (-6.14%)
At close: Jan 22, 2026, 4:00 PM EST
5.45
-0.05 (-0.91%)
After-hours: Jan 22, 2026, 4:00 PM EST
Actuate Therapeutics Employees
Actuate Therapeutics had 10 employees as of December 31, 2024. The number of employees increased by 5 or 100.00% compared to the previous year.
Employees
10
Change (1Y)
5
Growth (1Y)
100.00%
Revenue / Employee
n/a
Profits / Employee
-$2,411,999
Market Cap
127.84M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 10 | 5 | 100.00% |
| Dec 31, 2023 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ACTU News
- 10 days ago - Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 - GlobeNewsWire
- 16 days ago - Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers - GlobeNewsWire
- 5 weeks ago - Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 - GlobeNewsWire
- 4 months ago - Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months - GlobeNewsWire
- 4 months ago - Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock - GlobeNewsWire
- 4 months ago - Actuate Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 6 months ago - Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer - GlobeNewsWire
- 6 months ago - Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas - GlobeNewsWire